Jack Jr, 2012 - Google Patents
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will playJack Jr, 2012
View PDF- Document ID
- 11515282131862923170
- Author
- Jack Jr C
- Publication year
- Publication venue
- Radiology
External Links
Snippet
Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy coupled with the absence of any approved disease-modifying therapies at present position …
- 206010001897 Alzheimer's disease 0 title abstract description 347
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jack Jr | Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play | |
| Petrella et al. | Neuroimaging and early diagnosis of Alzheimer disease: a look to the future | |
| Hane et al. | Recent progress in Alzheimer’s disease research, part 3: diagnosis and treatment | |
| Kantarci et al. | Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1h mr spectroscopy metabolite measurements1 | |
| Norfray et al. | Alzheimer's disease: neuropathologic findings and recent advances in imaging | |
| Soldan et al. | Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical A lzheimer's disease | |
| Mosconi et al. | Early detection of Alzheimer’s disease using neuroimaging | |
| Jack et al. | Cerebral amyloid PET imaging in Alzheimer’s disease | |
| Moodley et al. | The Hippocampus in Neurodegenerative | |
| Langbaum et al. | Ushering in the study and treatment of preclinical Alzheimer disease | |
| Mistur et al. | Current challenges for the early detection of Alzheimer's disease: brain imaging and CSF studies | |
| Whitwell et al. | Rates of cerebral atrophy differ in different degenerative pathologies | |
| Ringman et al. | Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations | |
| Ewers et al. | Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia | |
| Giorgio et al. | Clinical use of brain volumetry | |
| Silverman et al. | Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease | |
| Cherbuin et al. | Neuroimaging and APOE genotype: a systematic qualitative review | |
| Galluzzi et al. | Supporting evidence for using biomarkers in the diagnosis of MCI due to AD | |
| Khan | Biomarkers in Alzheimer's disease | |
| Del Sole et al. | Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias | |
| Zhang et al. | MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease | |
| Solodkin et al. | In vivo parahippocampal white matter pathology as a biomarker of disease progression to Alzheimer's disease | |
| Wu et al. | Use of biomarkers in clinical trials of Alzheimer disease: from concept to application | |
| Mandel et al. | Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy | |
| Thordardottir et al. | Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study |